Approval · Notice of Compliance 35664 · 2025
PRO-ELETRIPTAN: Notice of Compliance 35664
Issued June 11, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35664
- Date
- June 11, 2025
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Administrative: Change in product name. Administrative: Update to labelling (to match Licensor)
- Canadian reference product
- RELPAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRO-ELETRIPTAN | 02489961 | Marketed |
| PRO-ELETRIPTAN | 02489988 | Marketed |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB